LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen

European Journal of Cancer

Volumn 40, Issue 12, 2004, Pages 1855-1861

  Berliere M ^a   Galant, C ^a   Marques, G ^a   Piette, Ph ^a   Duck, L ^a   Fellah, L ^a   Donnez, J ^a   Machiels, J P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Endocrine therapy; Gynaecological side effects; LH RH agonists; Ovarian ablation; Premenopausal breast cancer patients; Tamoxifen

Indexed keywords

GONADORELIN AGONIST; GOSERELIN; TAMOXIFEN; TAMOXIFEN CITRATE;

ADNEXA DISEASE; ADULT; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; DRUG SAFETY; ECHOGRAPHY; ENDOMETRIUM; FEMALE; FOLLOW UP; GYNECOLOGIC DISEASE; GYNECOLOGICAL EXAMINATION; HISTOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; OVARY METASTASIS; POLYP; PREMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; BREAST NEOPLASMS; FEMALE; GENITAL DISEASES, FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; PREMENOPAUSE; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 3843106185     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.04.019     Document Type: Article

References (43)

1. Klijn J.G., de Jong F.H., Lamberts S.W., Blankendrein M.A. LH-RH agonist treatment in clinical and experimental human breast cancer. J. Steroid Biochem. 23:1985;867-873
2. Jakesz R., Hausmaninger H., Kubista E., et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer. Austrian Breast and Colorectal Cancer Study Group Trials. J. Clin. Oncol. 20:2002;4621-4627
3. Jonat W., Kaufmann M., Sauerbrei W., et al. Goserelin versus cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer. The Zoladex Early Breast Cancer Research Association Study. J. Clin. Oncol. 20:2002;4628-4635
4. Bramwell V.H., Pritchard K.I. Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study? Eur. J. Cancer. 35:1999;1625-1627
5. Baum M, Houghton J, Odling Smee W, et al. On behalf of the ZIPP group. Adjuvant Zoladex in premenopausal patients with early breast cancer: results from the ZIPP breast trial. 2001, 10(Suppl 1), S32-S33 (abstract P64)
6. Pritchard K.I. Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift. J. Clin. Oncol. 20(24):2002;4611-4640
7. Davidson N, O'Neill A, Vikov A, et al. Effect of chemohormonal therapy in premenopausal node (+), receptor (+) breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5 188, INT 0101). Proc. Am. Soc. Clin. Oncol. 1999;67a (abstract 249)
8. Robertson J.F.R., Blamey R.W. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and postmenopausal women. Eur. J. Cancer. 39:2003;861-869
9. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992, 339, 71-85
10. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: an overview of the randomized trials. Lancet 1996, 348, 189-1196
11. Williamson K., Robertson J.F., Ellis I.O., Elston C.W., Nichoson R.I., Blamey R.W. Effect of LH-RH agonist, Zoladex, on ovarian histology. Br. J. Surg. 75:1988;595-596
12. Klijn J.G., Beex L.V., Manrix L., et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J. Natl. Cancer Inst. 92:2000;903-911
13. Boccardo F., Rubagotti A., Perrotta A., et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-/perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann. Oncol. 5:1994;337-342
14. Klijn J.G., Blamey R.W., Boccardo F., Tominaga T., Duchateau L., Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LH-RH) agonist versus LH-RH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J. Clin. Oncol. 19:2001;343-353
15. Cohen I., Tepper R., Figer A., Flex D., Shapira J., Beyth Y. Successful co-treatment with LH-RH agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure. Breast Cancer Res. Treat. 55:1999;119-125
16. Fan S.J., May V., Wang C.G., et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene. 20(1):2001;77-83
17. Eisinger F., Charaffe Jauffret G., Jacquemier J., Birnbaum D., Julan Reymier C., Sobol H. Tamoxifen and breast cancer risk in women harboring a BRCA 1 germline mutation: computed efficacy, effectiveness and impact. Int. J. Oncol. 18:2001;5-10
18. Osborne C.K., Jarman M., McCague R., et al. The importance of tamoxifen metabolism in tamoxifen- stimulated breast tumor growth. Cancer Chemother. Pharmacol. 34:1994;89-95
19. Recchia A., Sica G., De Filippis S., Saggio G., Rosselli M., Rea S. Goserelin as ovarian protective in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anti-Cancer Drugs. 13:2002;417-424
20. Berlière M., Charles A., Galant C., Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet. Gynecol. 91:1998;40-44
21. Berlière M., Radikov J., Galant C., Piette Ph., Marbaix E., Donnez J. Identification of women at high risk of developing endometrial cancer on tamoxifen. Eur. J. Cancer. 36:2000;S35-S36
22. Assikis V.J., Neven P., Jordan V.C., Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur. J. Cancer. 32:1996;1464-1476
23. Schwartz L.B., Krey L., Demopoulos R., Goldstein S.R., Nachtigall L., Mittat K. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Am. J. Obstet. Gynecol. 176:1997;129-137
24. Kommos F., Karck U., Prompeler H., et al. Steroid expression in endometria from women treated with tamoxifen. Gynecol. Oncol. 70:1998;188-191
25. Burger C.W., Prinssen H.M., Kenemans P. LH-RH agonist treatment of breast cancer and gynaecological malignancies: a review. Eur. J. Obstet. Gynecol. Reprod. Biol. 67:1996;27-32
26. Agorastos T., Bontis J., Vakiani A., Vavilis D., Constandinidis T. Treatment of endometrial hyperplasias with gonadotrophin-releasing hormone agonists: pathological, clinical, morphometric and DNA-cytometric data. Gynecol. Oncol. 65:1997;102-114
27. Grimbizis G., Tzalikis T., Tzioufa V., Kasapis M., Mantalenakis S. Regression of endometrial hyperplasia after treatment with the gonadotropin-releasing hormone analogue triptorelin: a prospective study. Hum. Reprod. 14:1999;478-484
28. Jadoul P., Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or well-differentiated endometrial adenocarcinoma. Fertil. Steril. 80(16):2003;1315-1324
29. Emong G., Ortmann O., Schulz K.D., Schally A.V. Growth-inhibitory actions of analogues of luteinizing hormone-releasing hormone on tumor cells. Trends Endocrin. Metab. 8:1997;355-362
30. Emong G., Muller V., Ortmann O., Schulz K.D. Effects of LH-RH analogues on mitogenic signal transduction in cancer cells. J. Steroid Biochem. Mol. Biol. 65:1998;199-206
31. Imai A., Takagi A., Horibe S., Takagi H., Tamaya T. Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J. Clin. Endocrinol. Metab. 83:1998;427-431
32. Imai A., Takagi A., Horibe S., Takagi H., Tamaya T. Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int. J. Oncol. 13:1998;97-100
33. Imai A., Ohno T., Lida K., Fiuseya T., Furui T., Tamaya T. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol. Oncol. 55:1994;114-118
34. Katzenellenbogen B.S., Choi I., Delage-Mouroux R., et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J. Steroid Biochem. Mol. Biol. 74:2000;279-285
35. Mc Gregor J.L., Jordan V.C. Basic guide to the mechanisms of antioestrogen action. Pharmacol. Rev. 50:1998;151-196
36. Fisher B., Constantino J.P., Redmond C.K., Fisher E.R., Wickerman D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B14. J. Natl. Cancer Inst. 86:1994;527-537
37. Rutqvist L.E., Johanson H., Signomklao T., Johanson U., Formander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. 87:1995;645-651
38. Bergman L., Beelen M.L., Galle M.P., Hollema H., Benraadt J., Van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centers' ALERT Group. Assesment of liver and endometrial cancer risk following tamoxifen. Lancet. 356:2000;881-887
39. Suh-Burgmann E.J., Goodman A. Surveillance for endometrial cancer in women receiving tamoxifen. Ann. Intern. Med. 13:1999;127-135
40. Devogelaer J.P., Dedeuxchaisnes N., Donnez J., Thomas K. LH-RH analogues in bone loss. Lancet. 1:1987;1498
41. Von Minckwitz G., Loibl S., Brunnert K., et al. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer - a multicentre, open, controlle, prospectively randomised trial. Eur. J. Cancer. 38:2002;2265-2271
42. Wickerham L., Fisher B., Bryant J., Costantino J., Bernstein L., Runowicz C. Association of tamoxifen and uterine sarcoma. J. Clin. Oncol. 20(11):2002;2758-2760
43. Gerber B., Krausse A., Muller H., Reimer T., Kulz T., Kundt G., Friese K. Ultrasonographic detection of asymptomatic endometrial cancer in postmenopausal patients offers no prognostic advantage over symptomatic disease discovered by uterine bleeding. Eur. J. Cancer. 37:2001;64-71